Korea Research Institute of Bioscience and Biotechnology

Pharmabcine Inc.

Semi Kim

Jin-San Yoo

Kyung Seop Ahn

Sei Ryang Oh

Hyeong Kyu Lee

Ok-Kyoung Kwon

Chae-Ok Yun

Sung-Woo Kim

Young-Guen Kwon

Do-Yun Kim

Weon-Sup Lee

Sang-Seok Koh

Hyeon-Mi Yoo

Young-Woo Park

Sang-Ryeol Shim

Too-Hyon Cho

Bo-Jeong Pyun

Dong-Sup Lee

Young Woo Park

Jong-Ho Park

Chae Ok Yun

Ji Hyun Park

Jung Hee Kim

Sung Woo Kim

Hyo Jeong Hong

Jeong Ho Yoon

Doo-Young Kim

Do Yun Kim

Dong Heon Lee

Weon Sup Lee

Jeong-Eun Kang

Hyun-Sook Jang

Mi-Hee Park

Dong-Heon Lee

Sam-Sook Sul

Geun-Bae Rha

Kwi-Hwa Kim

Chang Soo Yun

Ill Young Lee

Pilho Kim

Sang Ryeol Shim

Kwi Hwa Kim

So-Young Choi

Joon-Goo Jung

Jin San Yoo

Sang Seok Koh

Young Guen Kwon

Jae-Won Jeon

Nahm-Ju Kim

Bo Jeong Pyun

Joon-Chul Lee

Ha Young Jang

Yunhee Lee

Jae Won Jeon

Young-Soon Jang

Kiwon Jo

Young Kyu Park

Hyun Sook Jang

So Jeong Park

Byoung Whui Choi

Joon Chul Lee

Ji Eun Yuk

Dong Joon Ko

Mi Hee Park

Myoung Suk Choi

Mi-Ra Lee

Hye-Jin Min

Eun-Hee Nam

Yoosik Yoon

Heekyung Jung

Young-soon Jang

Hui Seong Kim

Kwang Pyo Lee

Hee Young Kang

Sam Sook Sul

Hyeon Mi Yoo

Nahm Ju Kim

Too Hyon Cho

Dong Sup Lee

Geun Bae Rha

Jeong Eun Kang

As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.

Pharmaceutical composition for cancer prevention and treatment containing peptide originated from C12orf59 protein as an active ingredient

The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine.

Method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5

The present invention relates to a 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The 2-hydroxyarylamide derivative prepared by the present invention is excellent in the inhibition of the activity of TMPRSS4 serine protease and the suppression of the infiltration of TMPRSS4-expressed cancer cells, and thus can be useful as a composition for preventing or treating cancer by inhibiting TMPRSS4 over-expressed in cancer cells, particularly, colorectal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, or stomach cancer cells.

2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.

Method of treating cancer with a composition containing a C12ORF59 protein

The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and byextract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma

The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-&#x3b2;1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma

The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.

Anticancer drug comprising inhibitor of TMPRSS4

Growing community of inventors

Daejeon, South Korea

Semi Kim